Cereno Scientific is a clinical-stage biopharmaceutical enterprise focused on pioneering innovative, disease-modifying therapies for rare cardiovascular and pulmonary conditions. The company harnesses an advanced epigenetic modulating platform targeting histone deacetylase (HDAC) enzymes to alter gene expression without changing the core DNA sequence. Its leading clinical pipeline includes assets like CS1 for pulmonary arterial hypertension and CS014 for pulmonary hypertension associated with interstitial lung disease.